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Feng Gao, MD, PhD,§ and Ramaswamy Govindan, MD†‡
Background: Although there has been a significant survival improve-
ment for patients with metastatic NSCLC enrolled in randomized trials,
it is not clear whether a similar benefit is seen in an unselected group of
patients. Therefore, we conducted a study to evaluate for survival
changes in a large national cancer registry database.
Patients and Methods: The Surveillance, Epidemiology, and End
Results (SEER) registry was queried for patients with NSCLC stage
IV, aged 21 years or older, and diagnosed between 1990 and 2005.
We analyzed four equally divided time periods between 1990 and
2005 (1990 to 1993 or period 1, 1994 to 1997 or period 2, 1998 to
2001 or period 3, and 2002 to 2005 or period 4) to determine changes
in overall survival for all patients and according to histology.
Results: We identified 129,337 patients meeting eligibility criteria.
There was a significant improvement in overall survival since period 1.
One-year and 2-year overall survival increased from 13.2 and 4.5%,
respectively, in period 1 to 19.4% and 7.8%, respectively, in period 4.
On multivariate analysis, survival for adenocarcinoma was increased
compared with squamous cell carcinoma only in period 4 (p  0.02).
Conclusions: There has been a modest but statistically significant
improvement in overall survival for stage IV NSCLC over the past
16 years. The recent differences in outcomes based on histology
observed in period 4 may reflect the increased activity of epidermal
growth factor receptor tyrosine kinase inhibitors in adenocarcinoma
compared with squamous cell carcinoma.
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Lung cancer is the most common cause of cancer-relateddeath in the United States, with 161,840 deaths estimated
by the American Cancer Society for the year 2008.1 Non-
small cell lung cancer (NSCLC) currently constitutes approx-
imately 87% of the lung cancer cases.2 Approximately 40%
of patients with newly diagnosed NSCLC present with met-
astatic disease.3
Survival improvement for NSCLC in the past 2 decades
has been modest. Breathnach et al.4 performed a combined
analysis of the Surveillance, Epidemiology, and End Results
(SEER) database and 33 North American phase III trials from
1973 to 1994. The SEER database showed improved 3-year
overall survival for patients with NSCLC, including all
stages, from 14.4% between 1972 and 1973 to 18.1% be-
tween 1993 and 1994. In patients with distant disease (ac-
cording to SEER historical staging system), which also in-
cludes patients with subtypes of T4 such as malignant pleural
effusion and direct extension into the sternum, vertebra, and
skeletal muscle, there was also a slight improvement in
median survival from 6.9 to 7.3 months during the same time
period. Among patients with stage III or IV treated in the
randomized clinical trials, median survival improved from
5.2 months between 1973 and 1983 to 5.8 months between
1984 and 1994.
Since 1990, there have been several changes in the
management of advanced NSCLC, including the develop-
ment of new chemotherapy agents and regimens,5 increasing
use of salvage chemotherapy,6,7 and the introduction of mo-
lecularly targeted therapies, specially the epidermal growth
factor tyrosine kinase inhibitors (TKIs).8 Although these
advances have been associated with improved response rates
and survival in clinical trials, there are only limited data
regarding the extent of this benefit in an unselected patient
population. Therefore, we performed an analysis of the SEER
database to evaluate for trends in survival for patients with
stage IV NSCLC over the last 16 years.
PATIENTS AND METHODS
Since its establishment in 1973, the National Cancer
Institute-funded SEER program has been collecting data on
demographics, pathologic, and clinical characteristics includ-
ing stage, initial treatment, and survival for newly diagnostic
cancer cases. The database expanded from nine registries
covering approximately 10% of the U.S. population from
1973 to 1991 (SEER-9) to 14% from 1992 to 1999 and 26%
since the year 2000 (SEER-17).
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We searched the April 2008 release of the SEER-17
registry data version 6.4.4,9 for patients with stage I to IV
NSCLC according to the modified AJCC, 3rd edition, aged
21 years or older, with active follow-up, and diagnosed
between 1990 and 2005. Patients with nonmetastatic disease
were evaluated only for the calculations of stage migration,
whereas the remaining of the study was focused on patients
with stage IV. Because there was no access to patient identity,
it was not necessary to obtain informed consent. The histology
was coded according to the International Classification of Dis-
eases for Oncology (0-3) into adenocarcinoma (8140–8147,
8255, 8260, 8310, 8323, 8480, 8481, 8490, 8550, and 8572),
squamous cell carcinoma (8050–8052 and 8070–8078), large
cell carcinoma (8012 and 8014), and other histologies, in-
cluding undifferentiated tumors (8020–8022) and carcino-
mas not otherwise specified or not defined as one of the three
most common histologies (8010, 8015, 8030–8036, and
8046). Large cell neuroendocrine carcinomas and bronchi-
oloalveolar carcinoma were excluded, the former due to
different behavior and lack of data before the year 2000 and the
latter due to a more indolent clinical course, distinct from other
subtypes of adenocarcinoma and NSCLC in general.
Demographic variables were defined as age at diagno-
sis, gender, and race (white, black, and other). Follow-up
cutoff was on December 31, 2005. Diagnostic periods were
subdivided into four groups as follows: 1990–1993 (period
1), 1994–1997 (period 2), 1998–2001 (period 3), and 2002–
2005 (period 4).
To evaluate for possible effects of the new SEER
registries, we performed a subset analysis including only
patients from registries available before the study, including
Atlanta, Connecticut, Detroit (Metropolitan), Hawaii, Iowa,
New Mexico, San Francisco-Oakland, Seattle (Puget Sound),
and Utah.
Statistical Analysis
Overall survival was defined as time from diagnosis to
death from any cause and patients alive were censored at the
time of last recording. Data analyses were performed accord-
ing to diagnostic period, with comparisons between consec-
utive periods, and subset analysis for each histologic subtype.
Overall survival was estimated using the Kaplan-Meier prod-
uct limit method and compared by log-rank test. Multivariate
Cox models were also fitted to evaluate whether diagnostic
period was an independent risk factor, while adjusting for
age, gender, race, and histologic subtypes. Statistical analyses
were performed using the standard package SAS version 9
(SAS institute, Cary, NC). A p value less than 0.05 was
considered significant, and all statistical tests were two sided.
RESULTS
Demographics
Among the 346,023 patients diagnosed in the four
periods, 37,347 (10.7%) had unknown stage. The percentages
of patients with unknown stage for periods 1 to 4 were 14.2%,
11.3%, 7.9%, and 11.2% respectively. Among those with
known stage classification, the proportions of patients with
metastatic disease from periods 1 to 4 were 39.3%, 38.9%,
41.2%, and 44.6%, respectively.
The demographics for the 129, 337 patients with stage
IV at presentation are described in Table 1. The median age
was 67.2  11.4 years (range, 21–105). There were 75,058
men (58%) and 54,259 women (42%). Whites represented the
majority of patients (82%), followed by African Americans
(12%) and others (6%). Adenocarcinoma was the most com-
mon histology (41%), followed by other histologies (34%),
squamous cell carcinoma (17%), and large cell carcinoma
(8%). The median follow-up time was 4 months (range,
1–191). Approximately 8% of the subjects were censored. As
reflected by the expanding SEER coverage, the number of
patients with the diagnosis of NSCLC entered in the registry
increased according to the year and period of diagnosis.
Univariate Survival Analysis
Overall survival at 1 and 2 years improved consistently
during each succeeding period (Figure 1 and Table 2). Over-
all survival at 1 and 2 years were 13.2% and 4.5% for period
1, 14.0% and 4.9% for period 2, 17.2% and 6.5% for period
3, and 19.4 and 7.8% for period 4, respectively. All the
improvements were statistically significant, including period
2 compared with period 1 (p  0.006), period 3 compared
with period 2 (p  0.0001), and period 4 compared with
period 3 (p 0.0001). A similar pattern was observed for the
four histologies, with modest improvement from periods 1 to
2 and more significant survival gains in subsequent periods.
However, median survival for all histologies remained stable
at approximately 4 months. Overall survival at 1 and 2 years
was significantly higher in adenocarcinoma and squamous
cell carcinoma compared with large cell carcinomas and other
histologies.
TABLE 1. Patient Demographics
Parameter Variables Number (%)
Age 21–30 124 (0.1)
31–40 1579 (1.2)
41–50 9570 (7.4)
51–60 24,100 (18.6)
61–70 39,165 (30.3)
71–80 39,675 (30.7)
81–90 14,132 (10.9)
91 992 (0.8)
Gender Male 75,078 (58.0)
Female 54,259 (42.0)
Race White 105,731 (81.7)
Black 15,178 (11.7)
Other 8428 (6.6)
Histology Adenocarcinoma 53,300 (41.2)
Squamous 22,944 (17.7)
Large cell 8842 (6.9)
Other 44,251 (34.2)
Diagnostic period 1990–1993 17,763 (13.8)
1994–1997 21,131 (16.3)
1998–2001 36,975 (28.6)
2002–2005 53,468 (41.3)
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Multivariate Survival Analysis
Factors associated with better survival in multivariate
analysis included younger age, female gender, ethnicity other
than whites or African Americans, adenocarcinoma or squa-
mous cell carcinoma histology, and successive diagnostic
periods (Table 3). Survival improvement was statistically
significant for all histology groups (Table 4). Survival was
significantly better for adenocarcinoma and squamous cell
carcinoma compared with large cell carcinoma or other his-
tologies in all diagnostic periods (Table 5). However, in-
creased survival for adenocarcinoma compared with squa-
mous cell was not observed until the fourth period.
Subset Analysis of Patients from Registries
Available Before 1990
Among the 129,337 patients, 69,130 (53.4%) were en-
rolled from the SEER registries available before 1990. In this
subset, the overall survival at 1 and 2 years were 13.4% and
4.6% for period 1, 14.3% and 5.1% for period 2, 17.2% and
6.6% in period 3, and 20.1% and 7.9% in period 4, respectively.
In a multivariate analysis, there was a statistically significant
difference in survival for all diagnostic periods. Comparing with
period 1, used as reference, the hazard ratios for periods 2, 3, and
4 were 0.975 (95% confidence interval [CI]: 0.954–0.998),
0.902 (95% CI: 0.883–0.922), and 0.824 (95% CI: 0.806–
0.843), respectively.
TABLE 2. Overall Survival According to Histology
Histology Period
Median
Survival (mo)
1-yr OS
(%)
2-yr OS
(%)
All histologies 1990–1993 4 13.2 4.6
1994–1997 4 14.1 4.9
1998–2001 4 17.2 6.5
2002–2005 4 19.3 7.8
Adenocarcinoma 1990–1993 4 15.5 5.4
1994–1997 4 16.1 5.7
1998–2001 4 20.4 7.9
2002–2005 5 23.3 9.9
Squamous 1990–1993 4 13.5 4.3
1994–1997 4 14.3 4.9
1998–2001 4 17.1 6.4
2002–2005 4 19.9 7.2
Large cell 1990–1993 3 11.5 4.3
1994–1997 3 12.5 3.8
1998–2001 4 14.8 5.7
2002–2005 4 16.6 6.6
Other 1990–1993 3 10.3 3.4
1994–1997 3 11.8 4.2
1998–2001 3 14 5.1
2002–2005 3 16.2 6.3
OS, overall survival.
FIGURE 1. Cumulative mortality rate according
to diagnostic period.
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DISCUSSION
The role of chemotherapy in previously untreated pa-
tients with advanced NSCLC was debatable until nearly 15
years ago.10–13 Before 1990, few drugs had consistent activity
against NSCLC, defined as response rate 15%, including
cisplatin, mytomicin C, vinblastine, vindesine, and ifosf-
amide. Since then, several novel chemotherapy agents have
been approved by the Food and Drug Administration for the
treatment of advanced NSCLC. Vinorelbine, paclitaxel, gem-
citabine, and docetaxel were approved between 1994 and
1999, whereas gefitinib, erlotinib, and pemetrexed were ap-
proved between 2003 and 2004.14 In a meta-analysis of 19
randomized clinical trials reported between 1994 and 2004,
Baggstrom et al.15 compared the efficacy of third-generation
agents with best supportive care or second-generation agents,
defined as platinum alone or in combination with etoposide,
vindesine, ifosfamide, or mitomycin. One-year survival with
single-agent third-generation agents was similar to second-
generation platinum-based combination therapy but signifi-
cantly improved when compared with best supportive care. In
a comparison between second and third generation platinum-
based regimens, both response rate and 1-year survival fa-
vored the third-generation combinations.
Data from randomized clinical trials have shown im-
proved 1-year survival from approximately 20% in early
1990s16 to approximately 38% in more recent studies using
platinum-based doublets.17–20 We conducted this study to
determine whether the survival improvement over the past 2
decades reported in controlled clinical trials is seen in uns-
elected representative patient population from the large SEER
database, possibly reflecting the true impact of recent ad-
vances on patients with NSCLC.
In keeping with published literature, we observed better
outcomes for women21 and younger patients.22 The effect of
race remains incompletely understood, and our dataset did
not show significant differences in outcomes between whites
and African Americans in the multivariate analysis. De-
creased access to optimal care, mostly surgical resection in
early stage,23 and higher percentage of advanced stage24 have
been postulated as possible causes for worse outcomes in this
population. When similar therapies were used, there were no
differences in outcomes according to race.25 Because our large
TABLE 3. Predictors for Improved Survival in Multivariate
Analysis
Parameter Variables Hazard Ratio (95% CI) p
Age (yr) 18–30 0.709 (0.580–0.866) 0.0008
31–40 0.787 (0.746–0.829) 0.0001
41–50 0.837 (0.818–0.857) 0.0001
51–60 0.905 (0.890–0.920) 0.0001
61–70 Reference
71–80 1.167 (1.150–1.184) 0.0001
81–90 1.440 (1.411–1.469) 0.0001
90 1.641 (1.538–1.751) 0.0001
Gender Female Reference
Male 1.128 (1.115–1.141) 0.0001
Race Other Reference
White 1.146 (1.119–1.174) 0.0001
Black 1.187 (1.154–1.221) 0.0001
Histology Adenocarcinoma Reference
Squamous 1.015 (0.999–1.032) 0.074
Large cell 1.129 (1.104–1.156) 0.0001
Others 1.194 (1.178–1.210) 0.0001
Period 1990–1993 Reference
1994–1997 0.973 (0.953–0.992) 0.006
1998–2001 0.887 (0.871–0.903) 0.0001
2002–2005 0.823 (0.808–0.838) 0.0001
CI, confidence interval.
TABLE 4. Multivariate Analysis for Survival Differences
among Histology Types According to Diagnostic Period
Histology Period Hazard Ratio (95% CI) p
Adenocarcinoma 1990–1993 Reference
1994–1997 0.974 (0.944–1.004) 0.09
1998–2001 0.887 (0.862–0.912) 0.0001
2002–2005 0.810 (0.788–0.833) 0.0001
Squamous 1990–1993 Reference
1994–1997 0.993 (0.949–1.038) 0.74
1998–2001 0.902 (0.867–0.940) 0.0001
2002–2005 0.853 (0.820–0.887) 0.0001
Large cell 1990–1993 Reference
1994–1997 0.974 (0.915–1.036) 0.39
1998–2001 0.884(0.834–0.937) 0.0001
2002–2005 0.847 (0.796–0.902) 0.0001
Other 1990–1993 Reference
1994–1997 0.961 (0.924–0.999) 0.04
1998–2001 0.881 (0.851–0.912) 0.0001
2002–2005 0.823 (0.796–0.851) 0.0001
CI, confidence interval.
TABLE 5. Multivariate Analysis for Survival Differences
According to Histology Subtype Within Each Diagnostic
Period
Period Histology Hazard Ratio (95% CI) p
1990–1993 Adenocarcinoma Reference
Squamous 0.990 (0.952–1.030) 0.62
Large cell 1.121 (1.068–1.177) 0.0001
Other 1.203 (1.159–1.250) 0.0001
1994–1997 Adenocarcinoma Reference
Squamous 1.007 (0.969–1.046) 0.72
Large cell 1.117 (1.063–1.173) 0.0001
Other 1.178 (1.140–1.217) 0.0001
1998–2001 Adenocarcinoma Reference
Squamous 0.997 (0.968–1.027) 0.85
Large cell 1.106 (1.060–1.153) 0.0001
Other 1.172 (1.144–1.200) 0.0001
2002–2005 Adenocarcinoma Reference
Squamous 1.033 (1.004–1.062) 0.02
Large cell 1.171 (1.117–1.240) 0.0001
Other 1.214 (1.189–1.240) 0.0001
CI, confidence interval.
Journal of Thoracic Oncology • Volume 4, Number 12, December 2009 Improving Survival in Stage IV NSCLC
Copyright © 2009 by the International Association for the Study of Lung Cancer 1527
database included only patients with stage IV disease, it elimi-
nated the biases caused by differences in stage at presentation.
The impact of histology on survival for patients with
advanced NSCLC has not been well delineated. Large retrospec-
tive studies have shown decreased survival for large cell carci-
noma26,27 and improved outcomes in squamous carcinoma.27,28
In a recent review, Hirsch et al.29 evaluated the role of
histology in advanced NSCLC. Among the 408 publications
surveyed between 1982 and 2007, 32 studies reported a
statistically significant associated between histology and
NSCLC outcomes. Results from chemotherapy trials showed
inconsistent results but among patients treated with TKIs;
however, adenocarcinoma was associated with improved re-
sponse rates and survival. Histology, in fact, became an
important factor for outcomes in NSCLC following the
results from Iressa Dose Evaluation in Advanced Lung
Cancer 130 and 231 trials, both showing increased response
rates for adenocarcinoma compared with other histologies.
This finding was confirmed in subsequent phase III studies
using gefitinib32 or erlotinib.33 Among patients treated with
pemetrexed, outcomes are better for adenocarcinoma com-
pared with squamous cell carcinoma.34 Although no signifi-
cant differences in survival between adenocarcinoma and
squamous cell carcinoma were observed on a multivariate
analysis in our study between periods 1 and 3, survival was
significantly better for patients with adenocarcinoma in pe-
riod 4 compared with patients with other histologies, possibly
due to the increased use of epidermal growth factor receptor
TKIs. However, it should be noted that the difference remains
small, perhaps due to the very poor outcomes in both sub-
groups.
Additional contributing factors for the increased sur-
vival in NSCLC include improved supportive therapy over
time and stage migration. Positron emission tomography
(PET) has been associated with a detection rate of unsus-
pected distant metastases in approximately 10% of patients
with NSCLC.35 With the Medicare approval for reimburse-
ment in 1998, an increasing number of patients are undergo-
ing PET scan during the staging process.36,37 Two retrospec-
tive studies showed increased percentage of patients
diagnosed with stage IV after the introduction of PET scan,
with both showing correspondent survival improvement in
the arbitrarily defined “PET period.”38,39 The stage migration
was confirmed in a large National Cancer Database Study
involving 813,312 patients with NSCLC and known stage,
which showed increased percentage of stage IV from 35.4 to
38.8% between the years 2000 and 2001, followed by a
plateau with minimal subsequent changes.3 The impact of
improved survival by stage migration may be explained by
the “Will Rogers phenomenon,”40 which is characterized by
the apparent paradox observed when moving elements from
one group to another raises the average for both donor and
recipients. In this case, patients with metastatic disease diag-
nosed only by PET scan are expected to have decreased
tumor burden and improved outcome compared with other
patients with metastatic disease. Therefore, the inclusion of
this subgroup originated from the stage migration is expected
to increase the overall survival for stage IV to a certain
degree. In our database, there was an increase in the percent-
age of patients with metastatic disease at presentation be-
tween periods 2 to 3 and 3 to 4. It is possible that this change
may account at least in part to the survival improvement in
stage IV disease.
The possibility of improved survival caused by the
addition of SEER registries during the study period was ruled
out by the almost identical survival rates observed in the
subset analysis restricted to registries available before 1990.
Despite the drawbacks from analyzing retrospective
database cohorts, our study provides insight into the changing
outcomes in advanced NSCLC over time and the impact of
recent advances in diagnosis and therapy beyond what has
been learnt studying highly selected group of patients en-
rolled in prospective studies. Although the development of
several new agents led to a statistically significant survival
improvement over the last 16 years, it is sobering that the
1-year survival has improved by only 6% during this time.
This improvement is certainly modest compared with the
extent of 1-year survival improvement reported in recent
clinical trials. Real progress can only be achieved with a
better understanding of tumor biology and development of
novel therapies.
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